Researchers from the University of Florida (UF) Health Cancer Institute in the US are developing a rapid, non-invasive urine test aimed at diagnosing prostate cancer and distinguishing it from other prostate-related conditions.
The approach, described in Analytical Chemistry, utilises a paper spray technique to measure metabolites in urine samples.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the UF Health Cancer Institute, a single, reliable test to differentiate aggressive, life-threatening cancers from slower-growing forms is lacking.
The new method involves applying a urine sample to paper cut in the shape of a triangle. An electric current is then applied, ionising the metabolites present in the urine.
The ionised molecules are measured with a mass spectrometer, allowing for identification within less than 30 seconds per sample. Unlike some existing urine-based prostate tests, the process does not require a digital rectal examination.
The study’s senior author, UF pathology, immunology and laboratory medicine associate professor Timothy Garrett said: “We need new screening technologies that can guide fast, efficient, patient-friendly and safe diagnosis and treatment options to manage aggressive disease.
“We are able to identify specific metabolites that allow for the clear diagnosis of prostate cancer from several prostate disorders such as enlargement or infection of the prostate gland.”
In their study, the research team evaluated urine samples from 40 participants, including healthy men, men with enlarged prostates, prostatitis, and those diagnosed with prostate cancer.
They identified 37 significant metabolic features across the different conditions, supporting the test’s ability to rapidly classify various prostate health disorders.
The team now intends to develop a large-scale study and assess the feasibility of at-home sample collection for broader use.
The study was supported by the UF Clinical & Translational Science Institute.
